Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 12:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1609–1632 of 35,388 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: alone Clear all

Conditions: Colitis, Ulcerative
Interventions: Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C; Biological
Lead sponsor: Alimentiv Inc.; Other
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 5
States / cities: Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more

Conditions: Chronic Rhinitis
Interventions: RhinAer Stylus, Sham; Device
Lead sponsor: Aerin Medical; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 13
States / cities: Roseville, California • Torrance, California • Plantation, Florida + 10 more

Conditions: Amputation, Prosthesis User, Prosthesis
Interventions: Myo-electric Gaming Interface; Device
Lead sponsor: Liberating Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Holliston, Massachusetts

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: Pembrolizumab, Bevacizumab, Binimetinib; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 53 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Locally Advanced or Metastatic Solid Tumors, NSCLC, HNSCC, Melanoma, TNBC, Esophageal Cancer, Gastric Cancer, Cervical Cancer, Colorectal Cancer, Urothelial Carcinoma, Clear Cell RCC, HCC
Interventions: Enzelkitug, Atezolizumab, Pembrolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 10
States / cities: San Francisco, California • Aurora, Colorado • Sarasota, Florida + 7 more

Conditions: Diffuse Large B-Cell Lymphoma
Interventions: Polatuzumab Vedotin, Rituximab, Gemcitabine, Oxaliplatin; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Jacksonville, Florida • Pembroke Pines, Florida • Ann Arbor, Michigan + 4 more

Conditions: Analgesia After Pacemaker, AICDS Implantation Pediatrics
Interventions: LA group, B Group; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 0 Years to 17 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infections, Bacterial
Interventions: GSK2140944 capsule, GSK2140944 tablet, Itraconazole capsule; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Carcinoma, Renal Cell
Interventions: Pegylated Alfa Interferon, sunitinib, erlotinib; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Ovarian Cancer, Fibroids, Uterine Cancer
Interventions: Bupivacaine, Liposomal bupivacaine; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Orange, California

Conditions: Kidney Failure, Kidney Diseases
Interventions: Testim, 1% testosterone gel; Drug
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 45 Years to 80 Years · Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Palo Alto, California • San Jose, California

Conditions: Gastroesophageal Reflux Disease, Barrett's Esophagus, Esophagus Adenocarcinoma
Interventions: Primary Care Provider Survey, Gastroenterologist Survey, Patient Survey; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years
Enrollment: 725 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 7
States / cities: Aurora, Colorado • Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Prostate Cancer
Interventions: High-resolution micro-ultrasound; Device
Lead sponsor: University of Alberta; Other
Eligibility: 18 Years and older · Male only
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Allogeneic Stem Cell Transplant, Leukemia, Non-Hodgkins, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions: cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Migraine in Children
Interventions: Valproic Acid (VPA), Dihydroergotamine (DHE); Drug
Lead sponsor: Kimberly S Jones; Other
Eligibility: 10 Years to 18 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Anxiety, Depression, Stress
Interventions: Project THINK, Project SHARE; Behavioral
Lead sponsor: Harvard University; Other
Eligibility: 10 Years to 16 Years
Enrollment: 597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer
Interventions: ASP5541, Prednisone, Prednisolone, abiraterone acetate, Adrenocorticotropic hormone; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 12
States / cities: Huntsville, Alabama • San Diego, California • Tampa, Florida + 9 more

Conditions: Pyoderma Gangrenosum
Interventions: Platelet rich plasma therapy; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anesthesia, Local, Phrenic Nerve Paralysis, Upper Extremity Injury, Shoulder Injury
Interventions: Interscalene brachial plexus nerve block, Erector spinae plane block; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Fibrinogen Abnormality, Telomere Length, Mean Leukocyte, Atopic, Acute Infection, Inflammatory Response, Self-regulation
Interventions: Care Coordination, Resiliency Clinic, Usual Care; Behavioral
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 3 Months to 11 Years
Enrollment: 555 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Oakland, California

Conditions: Prostate Cancer
Interventions: Stereotactic Body Radiation Therapy (SBRT), Prostatectomy, Quality of Life Questionnaires; Radiation · Procedure · Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Symptomatic Neurogenic Orthostatic Hypotension
Interventions: ampreloxetine, Placebo; Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 30 Years and older
Enrollment: 195 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 23
States / cities: Sun City, Arizona • Long Beach, California • Palo Alto, California + 19 more

Conditions: Kidney Failure
Interventions: IVIg and rituximab; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: SARS-CoV2 Infection
Interventions: Testing for SARS CoV2 Antigen and Antibody; Device
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Newark, New Jersey

Search by objective public record fields.

Determination of the Optimal Treatment Target in Ulcerative Colitis

RhinAer Procedure for Treatment of Chronic Rhinitis Study

Myoelectric Game Training and Outcomes

Study of Pembrolizumab, Binimetinib, and Bevacizumab in Patients With Refractory Colorectal Cancer

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors

A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Truncal Ultrasound Guided Regional Anesthesia for Implantation and Revision of Automatic Implantable Cardioverter Defibrillators (AICDs) and Pacemakers in Pediatric Patients

Relative Bioavailability, Safety, Tolerability, Pharmacokinetics (PK) and Food Effect Study of GSK2140944 in Healthy Subjects

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Pilot Study of Liposomal Bupivacaine Redosing in Patients Undergoing Major Gynecologic Procedures

Testosterone Replacement Therapy in Advanced Chronic Kidney Disease

Survey Study on Barrett's Esophagus Screening

Micro-UltraSound In Cancer - Active Surveillance

Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic Disorders

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

Project THINK: Trial of a Brief Cognitive Restructuring Intervention

A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer

Autologous Platelet-Rich Plasma Therapy in the Treatment of Pyoderma Gangrenosum

Erector Spinae Plane Versus Interscalene Blocks for Shoulder Surgery

Pediatric ACEs Screening and Resiliency Study

Dose Escalation Study of Preoperative SBRT for High Risk Prostate Cancer

Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

Rutgers Pilot for Dental Health Care Worker SARS-CoV-2 Testing